Retatrutide at ObesityWeek 2026: What Is Lilly Presenting, and Is Any of It New?

What Is Lilly Presenting on Retatrutide at ObesityWeek 2026?

On 14 November 2026, Eli Lilly and Company published its programme for ObesityWeek® 2026, the annual meeting of The Obesity Society, which runs 14–17 November 2026 in the Washington, D.C. area.[1] The release covers four programmes: tirzepatide (Zepbound), orforglipron (Foundayo), the eloralintide–tirzepatide combination Lilly calls EloraTZP, and retatrutide, its investigational once-weekly GIP/GLP-1/glucagon triple receptor agonist.

For retatrutide, the release lists a joint retatrutide and Zepbound oral session on Sunday 15 November 2026, 5:00–6:30 pm ET.[1][2] The data highlighted come from TRIUMPH-1 (NCT05929066), the 80-week Phase 3 master trial in adults with obesity or overweight, and specifically from its two nested “basket” sub-studies: one in obstructive sleep apnea (OSA) and one in knee osteoarthritis.[3]

Is Any of the Retatrutide Data Actually New?

Mostly not, as far as the headline figures go. The two TRIUMPH-1 numbers quoted in Lilly’s release match figures the company first disclosed at the American Diabetes Association meeting on 6 June 2026, and both sub-studies have since been reported in the New England Journal of Medicine.[4][5][6] The table sets the ObesityWeek figures against their earlier outings. All values are as reported by the sponsor in a placebo-controlled trial of an investigational drug.

Secondary coverage of the release also repeats two figures from sister trials: an AHI change of 28.4 events per hour (48.1%) at 80 weeks in TRIUMPH-2, and a WOMAC pain change of 4.5 points (75.8%) at 68 weeks in TRIUMPH-4.[2] Both were public before this meeting; we covered them in our summaries of the NEJM sleep-apnea report and the NEJM knee-osteoarthritis paper.

What may be new is what a 90-minute oral session can carry that a press release cannot: additional pre-specified secondary endpoints, subgroup breakdowns and adverse-event detail. Until the slides or abstracts are examined, that remains a possibility, not a finding.

How Should Researchers Read “Up To” Figures in a Conference Release?

Three reading points apply to this release and to conference announcements generally.

• “Up to” means the best-performing arm. TRIUMPH-1 tested several retatrutide dose arms against placebo. A figure introduced with “up to” is the largest mean change across arms, by convention the highest dose, and is not the average across everyone randomised. The placebo-arm change is needed to interpret it, and the release excerpts we reviewed do not foreground it.
• The estimand matters. Lilly’s obesity releases usually lead with an “efficacy estimand” (assuming participants stayed on assigned treatment). The treatment-regimen estimand, which counts everyone regardless of discontinuation, is typically more conservative and is the one regulators weigh. The peer-reviewed papers report both.
• Abstracts are not papers. Conference abstracts are short, lightly reviewed and embargoed as a block; The Obesity Society lifted its embargo on accepted ObesityWeek 2026 abstracts at 12:00 pm ET on 14 November.[7] Where a full journal report exists, as it does for both TRIUMPH-1 sub-studies, the journal version is the citable record.

Design also shapes interpretation. The OSA and knee sub-studies are nested inside one master protocol and share its randomisation and placebo arm, a structure explained in our guide to the TRIUMPH basket-trial design. TRIUMPH-1 additionally has a pre-specified extension to 104 weeks, so 80-week figures are not the trial’s final word.[3]

What Else Is in Lilly’s ObesityWeek Programme?

The genuinely newer material in the release sits outside retatrutide. As reported by Lilly and secondary coverage:[1][2]

• EloraTZP (eloralintide + tirzepatide). An oral session on 15 November presents Phase 2 data in adults with obesity or overweight and type 2 diabetes. Topline results were first shown at EASD on 30 September 2026; see our EloraTZP Phase 2b summary.
• Eloralintide. Participant exit-interview (qualitative, self-reported) data from a Phase 2 study.
• Orforglipron (Foundayo). A real-world survey of user-reported experience with the once-daily oral agent.
• Tirzepatide (Zepbound). Additional analyses, which one outlet reports include 72-week data in adolescents. We have not verified that item against the abstract.

Tirzepatide is a licensed medicine in several jurisdictions; retatrutide, eloralintide and EloraTZP are not licensed anywhere. The programme therefore mixes post-approval analyses with investigational-stage data, and the two should not be read at the same evidential level.

Does ObesityWeek Change Retatrutide’s Regulatory Status?

No. Retatrutide has no marketing authorisation from the FDA, the MHRA, the EMA or any other regulator. Lilly has said it plans to submit the molecule for US review in the first quarter of 2027, after completing its manufacturing (CMC) package.[8] A conference presentation is a scientific-communication event; it neither starts nor shortens a regulatory review. Our retatrutide FDA approval timeline tracks the dated milestones.

Retatrutide reference material is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. The trial data above describe Eli Lilly’s investigational product in supervised clinical trials and make no claim about any Velox product. See our Research Use Policy and MHRA Statement.

What Is Still Not Known?

Three things to keep open. First, session content: this article was written before the 15 November session and relies on the release, so any data shown only on slides is not reflected here. Second, venue wording: Lilly’s release places the meeting in Washington, D.C., while The Obesity Society lists the venue as the Gaylord National Resort in nearby National Harbor, Maryland; the two describe the same event. Third, longer follow-up: the 104-week TRIUMPH-1 extension, the TRIUMPH-Outcomes cardiovascular and kidney trial (NCT06383390) and the head-to-head study against tirzepatide have not reported.[9]

Sourcing note: this summary relies on Lilly’s 14 November 2026 release as republished by wire services and on secondary coverage of it. Readers who need exact wording, session titles or presenter names should consult the release and the ObesityWeek programme directly.

Frequently Asked Questions